Xenleta · 4.5 Interaction with other medicinal products and other forms of interaction · 1

HOS-099123 · has-adverse-reaction-information · PDF-Seite 8

Summary of the safety profile The most frequently reported adverse reactions are diarrhoea (7%), nausea (4%), vomiting (2%), hepatic enzyme elevation (2%), headache (1%), hypokalaemia (1%), and insomnia (1%). Gastrointestinal disorders were predominantly associated with the oral formulation of lefamulin and led to treatment discontinuation in <1%. The most frequently reported serious adverse reaction is atrial fibrillation (<1%). Tabulated list of adverse reactions Based on pooled data from Phase 3 trials for both intravenous and oral formulations, the following adverse reactions have been identified with lefamulin. Adverse reactions are classified according to System Organ Class and frequency. Frequency categories are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), and not known (cannot be estimated from the available data). Table 3: Frequency of adverse reactions by system organ class from clinical trials System organ class Common Uncommon Infections and infestations Clostridioides difficile colitis Oropharyngeal candidiasis Vulvovaginal mycotic infection Blood and lymphatic system Anaemia disorders Thrombocytopenia Metabolism and nutrition Hypokalaemia disorders Psychiatric disorders Insomnia Anxiety Nervous system disorders Headache Dizziness Somnolence Cardiac disorders Electrocardiogram QT Atrial fibrillation prolonged Palpitations Respiratory, thoracic and Oropharyngeal pain mediastinal disorders Gastrointestinal disorders Diarrhoea Abdominal pain Nausea Abdominal pain upper Vomiting Constipation Dys

Auszug; vollständigen Abschnitt im Original lesen.

HOS-099129 · has-adverse-reaction-information · PDF-Seite 21

Summary of the safety profile The most frequently reported adverse reactions are administration site reactions (7%), diarrhoea (7%), nausea (4%), vomiting (2%), hepatic enzyme elevation (2%), headache (1%), hypokalaemia (1%), and insomnia (1%). Administration site reactions apply to intravenous administration and led to treatment discontinuation in <1%. Gastrointestinal disorders were predominantly associated with the oral formulation of lefamulin and led to treatment discontinuation in <1%. The most frequently reported serious adverse reaction is atrial fibrillation (<1%). Tabulated list of adverse reactions Based on pooled data from Phase 3 trials for both intravenous and oral formulations, the following adverse reactions have been identified with lefamulin. Adverse reactions are classified according to System Organ Class and frequency. Frequency categories are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), and not known (cannot be estimated from the available data). Table 3: Frequency of adverse reactions by system organ class from clinical trials System organ class Common Uncommon Infections and infestations Clostridioides difficile colitis Oropharyngeal candidiasis Vulvovaginal mycotic infection Blood and lymphatic system Anaemia disorders Thrombocytopenia Metabolism and nutrition Hypokalaemia disorders Psychiatric disorders Insomnia Anxiety Nervous system disorders Headache Dizziness Somnolence Cardiac disorders Electrocardiogram QT Atrial fibrillation prolonged Palpitations Respiratory, thoracic and Oropharyngeal pain mediastinal disorders Gastrointestinal disorders Diarrhoea Abdominal pain Nausea Abdominal pain upper

Auszug; vollständigen Abschnitt im Original lesen.

HOS-099119 · has-contraindication-information · PDF-Seite 3

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Hypersensitivity to any other members of the pleuromutilin class. Coadministration with moderate or strong inducers of CYP3A (e.g. efavirenz, phenytoin, rifampicin) or with strong inhibitors of CYP3A (e.gclarithromycin, itraconazole, ritonavir) (see section 4.5). Coadministration with CYP3A substrates (e.g. antipsychotics, erythromycin, tricyclic antidepressants) that prolong the QT interval (see section 4.5). Coadministration with medicinal products that prolong the QT interval such as Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmic medicinal products (see section 4.5). Known QT prolongation. Electrolyte disturbances, particularly uncorrected hypokalemia. Clinically relevant bradycardia, unstable congestive heart failure, or history of symptomatic ventricular arrhythmias. Coadministration with sensitive CYP2C8 substrates (e.g. repaglinide) (see section 4.5).

HOS-099125 · has-contraindication-information · PDF-Seite 16

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Hypersensitivity to any other members of the pleuromutilin class. Coadministration with moderate or strong inducers of CYP3A (e.g. efavirenz, phenytoin, rifampicin) (see section 4.5). Coadministration with CYP3A substrates (e.g. antipsychotics, erythromycin, tricyclic antidepressants) that prolong the QT interval (see section 4.5). Coadministration with medicinal products that prolong the QT interval such as Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmic medicinal products (see section 4.5). Known QT prolongation. Electrolyte disturbances, particularly uncorrected hypokalemia. Clinically relevant bradycardia, unstable congestive heart failure, or history of symptomatic ventricular arrhythmias. Coadministration with sensitive CYP2C8 substrates (e.g. repaglinide) (see section 4.5).

HOS-099124 · has-indication-information · PDF-Seite 15

Xenleta is indicated for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed (see section 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.

HOS-099118 · has-indication-information · PDF-Seite 2

Xenleta is indicated for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed (see section 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.

HOS-099121 · has-interaction-information · PDF-Seite 4

Pharmacodynamic interactions Co-administration of lefamulin with other medicinal products known to prolong the QT interval is contraindicated (see section 4.3). Pharmacokinetic interactions Effects of other products on lefamulin Use with moderate and strong CYP3A/P-gp inducers Medicinal products that are moderate or strong CYP3A inducers (e.g. rifampicin, St John´s wort [Hypericum perforatum], carbamazepine, phenytoin, bosentan, efavirenz, primidone) could significantly decrease lefamulin plasma concentration and may lead to reduced therapeutic effect of lefamulin. Co-administration of such medicinal products with lefamulin is contraindicated (see section 4.3). 4 Use with strong CYP3A/P-gp inhibitors Medicinal products that are strong CYP3A and P-gp inhibitors (e.g. clarithromycin, diltiazem, itraconazole, ketoconazole, nefazodone, posaconazole, ritonavir-containing regimens, voriconazole) may alter absorption of lefamulin and therefore increase lefamulin plasma concentrations. Co- administration of such medicinal products or grapefruit juice with lefamulin is contraindicated (see section 4.3). Potential for lefamulin to affect other medicinal products Lefamulin is a moderate CYP3A inhibitor but has no induction potential. Co-administration of oral lefamulin with medicinal products metabolised by CYP3A such as alprazolam, alfentanil, ibrutinib, lovastatin, simvastatin, triazolam, vardenafil, and verapamil may result in increased plasma concentrations of these medicinal products (see Table 2). Co-administration of lefamulin with medicinal products metabolised by CYP2C8 (e.g. repaglinide) may result in increased plasma concentrations of these medicinal products. Co-administration with sensitive substrates of CYP2C8 is contraindicated (see section 4.3 and Table 2). In a clinical drug-drug interaction study, no clinically relevant interaction was observed when lefamulin was co-administered with the P-gp substrate digoxin. Clinical drug interaction studies with lefamulin and substrates of other transporters have not been performed. In-vitro studies indicated that lefamulin acts as an inhibitor of OATP1B1, OATP1B3, BCRP, OCT1 and MATE1 transporters. Therefore, caution is recommended when co-administering lefamulin with sensitive substrates of these transporters, especially for those substrates with a narrow therapeutic window. Table 2 summarises effects on plasma concentrations of lefamulin and on co-

Auszug; vollständigen Abschnitt im Original lesen.

HOS-099127 · has-interaction-information · PDF-Seite 17

Pharmacodynamic interactions Co-administration with other medicinal products known to prolong the QT interval is contraindicated (see section 4.3). Pharmacokinetic interactions 17 Effects of other products on lefamulin Use with moderate and strong CYP3A/P-gp inducers Medicinal products that are moderate or strong CYP3A inducers (e.g. rifampicin, St John´s wort [Hypericum perforatum], carbamazepine, phenytoin, bosentan, efavirenz, primidone) could significantly decrease lefamulin plasma concentration and may lead to reduced therapeutic effect of lefamulin. Co-administration of such medicinal products with lefamulin is contraindicated (see section 4.3). Potential for lefamulin to affect other medicinal products Co-administration of lefamulin with sensitive CYP2C8 substrates such as repaglinide may result in increased plasma concentrations of these medicinal products. Co-administration with sensitive substrates of CYP2C8 is contraindicated (See section 4.3 and Table 2). In a clinical drug-drug interaction study, no clinically relevant interaction was observed when lefamulin was co-administered with the P-gp substrate digoxin. Clinical drug interaction studies with lefamulin and substrates of other transporters have not been performed. In vitro studies indicated that lefamulin acts as an inhibitor of OATP1B1, OATP1B3, BCRP, OCT2 and MATE1 transporters. Therefore, caution is recommended when co-administering lefamulin with sensitive substrates of these transporters, especially for those substrates with a narrow therapeutic window. Table 2 summarises effects on plasma concentrations of lefamulin and on co-administered medicinal products expressed as least-square mean ratios (90% confidence interval). The direction of the arrow indicates the direction of the change in exposures (Cmax and AUC), where ↑ indicates an increase more than 25%, ↓ indicates a decrease more than 25%, and ↔ indicates no change (equal to or less than 25% decrease or increase). The table below is not all inclusive. Table 2: Interactions and dose recommendations of intravenous Xenleta with other medicinal products Medicinal product by therapeutic Effect on areas/possible medicinal Cmax AUC Clinical comments mechanism of product levels interaction ANTIDEPRESSANTS Fluvoxamine* Not studied No dose adjustment of 100 mg twice d

Auszug; vollständigen Abschnitt im Original lesen.

HOS-099122 · has-pregnancy-information · PDF-Seite 7

Women of childbearing potential Women of childbearing potential should use effective contraception during treatment with Xenleta. Women taking oral contraceptives should use an additional barrier method of contraception. Pregnancy There are no data from the use of lefamulin in pregnant women. Studies in animals have shown increased incidence of stillbirth (see section 5.3). Animal studies are insufficient with respect to embryo-foetal development (see section 5.3). Xenleta is not recommended during pregnancy. Breast-feeding It is unknown whether lefamulin/metabolites are excreted in human milk. Available pharmacokinetic data in animals have shown excretion of lefamulin/metabolites in milk (see section 5.3). A risk to the newborns/infants cannot be excluded. 7 Breast-feeding should be discontinued during treatment with Xenleta. Fertility The effects of lefamulin on fertility in humans have not been studied. Lefamulin caused no impairment of fertility or reproductive performance in rats (see section 5.3).

HOS-099128 · has-pregnancy-information · PDF-Seite 20

Women of childbearing potential Women of childbearing potential should use effective contraception during treatment with Xenleta. Women taking oral contraceptives should use an additional barrier method of contraception. Pregnancy There are no data from the use of lefamulin in pregnant women. Studies in animals have shown increased incidence of stillbirth (see section 5.3). Animal studies are insufficient with respect to embryo-foetal development (see section 5.3). Xenleta is not recommended during pregnancy. Breast-feeding It is unknown whether lefamulin/metabolites are excreted in human milk. Available pharmacokinetic data in animals have shown excretion of lefamulin/metabolites in milk (see section 5.3). A risk to the newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with Xenleta. Fertility The effects of lefamulin on fertility in humans have not been studied. Lefamulin caused no impairment of fertility or reproductive performance in rats (see section 5.3).

HOS-099126 · has-warning-information · PDF-Seite 16

Prolongation of QTc interval and potential QTc-interval prolongation-related clinical conditions Changes in cardiac electrophysiology have been observed in nonclinical and clinical studies with lefamulin. In clinical trials in patients with community-acquired pneumonia, the mean change in QTcF from baseline to Day 3 to 4 was 11.4 msec. Post-baseline QTcF increases >30 msec and >60msec were seen in 17.9% and in 1.7% of patients, respectively, and were more frequent following 16 intravenous lefamulin dosing compared to oral dosing. The magnitude of QT prolongation may increase with increasing concentrations of lefamulin or increasing the rate of infusion of the intravenous formulation. Therefore, the recommended dose and infusion rate should not be exceeded. Lefamulin should be used with caution in patients with renal failure who require dialysis because metabolic disturbances associated with renal failure may lead to QT prolongation. Lefamulin should be used with caution in patients with mild, moderate, or severe cirrhosis because metabolic disturbances associated with hepatic insufficiency may lead to QT prolongation. Clostridioides (formerly known as Clostridium) difficile- associated diarrhoea C. difficile associated diarrhoea (CDAD) has been reported with lefamulin and may range in severity from mild diarrhoea to fatal colitis. CDAD must be considered in all patients who present with diarrhoea during or subsequent to the administration of lefamulin (see section 4.8). Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial medicinal products. If CDAD is suspected or confirmed, ongoing antibacterial medicinal product use not directed against C. difficile may need to be discontinued. Appropriate supportive measures together with the administration of specific treatment for Clostridioides difficile should be considered. Non-susceptible microorganisms Prolonged use may result in the overgrowth of non-susceptible organisms which may require interruption of treatment or other appropriate measures. Effects on hepatic transaminases Monitoring of hepatic transaminases (ALT, AST) is recommended during treatment, especially in patients whose transaminases are elevated at baseline (see section 4.8). Hepatic impairment Patients with moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment have reduced le

Auszug; vollständigen Abschnitt im Original lesen.

HOS-099120 · has-warning-information · PDF-Seite 3

Prolongation of QTc interval and potential QTc-interval prolongation-related clinical conditions Changes in cardiac electrophysiology have been observed in non-clinical and clinical studies with lefamulin. In clinical trials in patients with community-acquired pneumonia, the mean change in QTcF from baseline to Day 3 to 4 was 11.4 msec. Post-baseline QTcF increases >30 msec and >60msec were seen in 17.9% and in 1.7% of patients, respectively, and were more frequent following intravenous lefamulin dosing compared to oral dosing. Lefamulin should be used with caution in patients with renal failure who require dialysis because metabolic disturbances associated with renal failure may lead to QT prolongation. Lefamulin should be used with caution in patients with mild, moderate, or severe cirrhosis because 3 metabolic disturbances associated with hepatic insufficiency may lead to QT prolongation. Clostridioides (formerly known as Clostridium) difficile- associated diarrhoea C. difficile associated diarrhoea (CDAD) has been reported with lefamulin and may range in severity from mild diarrhoea to fatal colitis. CDAD must be considered in all patients who present with diarrhoea during or subsequent to the administration of lefamulin (see section 4.8). Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial medicinal products. If CDAD is suspected or confirmed, ongoing antibacterial medicinal product use not directed against C. difficile may need to be discontinued. Appropriate supportive measures together with the administration of specific treatment for Clostridioides difficile should be considered. Non-susceptible microorganisms Prolonged use may result in the overgrowth of non-susceptible organisms which may require interruption of treatment or other appropriate measures. Effects on hepatic transaminases Monitoring of hepatic transaminases (ALT, AST) is recommended during treatment, especially in patients whose transaminases are elevated at baseline (see section 4.8). Hepatic impairment Patients with moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment have reduced lefamulin protein binding compared to healthy subjects or subjects with mild (Child-Pugh Class A) hepatic impairment. Treatment should be initiated in patients with moderate or severe hepatic impairment only after a careful benefit/ri

Auszug; vollständigen Abschnitt im Original lesen.